Summit Therapeutics (SMMT) EBIT (2016 - 2024)
Historic EBIT for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' EBIT fell 8120.41% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$180.7 million, marking a year-over-year decrease of 9234.84%. This contributed to the annual value of -$226.0 million for FY2024, which is 6292.99% up from last year.
- Latest data reveals that Summit Therapeutics reported EBIT of -$65.6 million as of Q4 2024, which was down 8120.41% from -$58.4 million recorded in Q3 2024.
- Summit Therapeutics' 5-year EBIT high stood at -$7.6 million for Q1 2020, and its period low was -$65.6 million during Q4 2024.
- For the 4-year period, Summit Therapeutics' EBIT averaged around -$32.2 million, with its median value being -$20.5 million (2023).
- Its EBIT has fluctuated over the past 5 years, first surged by 448.54% in 2020, then tumbled by 18488.19% in 2024.
- Quarter analysis of 4 years shows Summit Therapeutics' EBIT stood at -$7.6 million in 2020, then tumbled by 167.13% to -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then crashed by 81.2% to -$65.6 million in 2024.
- Its last three reported values are -$65.6 million in Q4 2024, -$58.4 million for Q3 2024, and -$36.2 million during Q4 2023.